Real‐world effectiveness of sodium‐glucose cotransporter‐2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria
Authors' conclusion
In a real-world study of primarily older non-diabetic adults with CKD, SGLT2 inhibition was associated with a slower rate of kidney function decline, regardless of baseline UACR level.
Study context
- Population
- Adults without diabetes with estimated glomerular filtration rate (eGFR) 25–60 mL/min/1.73 m² who initiated dapagliflozin or empagliflozin (September 2020–November 2022), Maccabi Healthcare Services, Israel; mean age 72.8 ± 11.8 years, 26% femalemedian follow-up 527 days
- Participants
- 354 adults
- Exposure
- eGFR slope after vs before SGLT2i initiation
- Outcome
- Change in annual eGFR slope (baseline vs follow-up)
Methodological detailsreal-world, before-after (pre-post) comparison of eGFR slopes, single health maintenance organization
- Real-world
- Before-after (pre-post) comparison of eGFR slopes
- Single health maintenance organization
Main finding
As reported in the abstract
Annual eGFR slope
Baseline
−5.6
mean · ± 7.7 · mL/min/1.73 m² per year
Follow-up
−1.7
mean · ± 6.8 · mL/min/1.73 m² per year
P < 0.001
Observational data: associations, not effects.
Further findings
eGFR slope by baseline urinary albumin to creatinine ratio (UACR)
- Effect independent of UACR
Original publication
Real‐world effectiveness of sodium‐glucose cotransporter‐2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria. Diabetes Obes Metab. Published 28 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →